| +0.66 / +0.75%|
Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. The company operates its business through two segments: Specialty Pharmaceuticals and Global Medical Imaging. The Specialty Pharmaceuticals segment develops, manufactures and sells branded and generic drugs, including EXALGO, indicated for the treatment of moderate to severe pain in opioid-tolerant patients; and GABLOFEN, which are injections indicated for use in the management of severe spasticity of cerebral or spinal origin. The Global Medical Imaging segment develops, manufactures and markets contrast media & delivery systems and nuclear imaging agents. Its contrast media offerings include iodine-and gadolinium-containing injectable products for diagnostic imaging applications, such as computed tomography (CT) and magnetic resonance imaging (MRI) under Optiray and Optimark brands. Mallinckrodt was founded on January 9, 2013 and is headquartered in Dublin, Ireland.
|Mark C. Trudeau||President, Chief Executive Officer & Director|
|Matthew K. Harbaugh||Chief Financial Officer & Senior Vice President|
|Mario Saltarelli||Chief Science Officer & Senior Vice President|
|Peter G. Edwards||Senior Vice President & General Counsel|
|Hugh M. Oneill||President-Specialty Pharmaceuticals & Senior VP|